The company said, “The Company expects full year 2024 GAAP operating expenses of $210 million to $220 million, including estimated non-cash stock-based compensation expense of approximately $40 million, and full year collaboration revenue of approximately $3 million related to the Sanofi agreement. The Company expects to end 2024 with a balance of approximately $180 million in cash and investments, and for the balance to enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2026.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IGMS:
- IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Short Report: Childrenâs Place bears undeterred by Mithaq Capital involvement
- PayPal downgraded, United Airlines upgraded: Wall Street’s top analyst calls
- IGM Biosciences upgraded to Outperform from Sector Perform at RBC Capital
- IGM Biosciences price target raised to $9.50 from $8 at BofA
